thiazoles has been researched along with Prostatic Diseases in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matsuo, T; Miyata, Y; Sakai, H | 1 |
| Funahashi, Y | 1 |
| Al-Shukri, S; Barkin, J; Drake, MJ; Fianu-Jonasson, A; Herschorn, S; Huang, M; MacDiarmid, S; Siddiqui, E; Stoelzel, M | 1 |
| Borg, J; Crook, J; Ma, C; Patil, N; Pond, G; Wallace, K; Zhou, D | 1 |
3 trial(s) available for thiazoles and Prostatic Diseases
| Article | Year |
|---|---|
Editorial Comment from Dr Matsuo et al. to Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial.
Topics: Acetanilides; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Diseases; Thiazoles | 2022 |
Editorial Comment from Dr Funahashi to Mirabegron for treatment of erectile dysfunction concomitant with lower urinary tract symptoms in patients with benign prostatic obstruction: A randomized controlled trial.
Topics: Acetanilides; Erectile Dysfunction; Humans; Lower Urinary Tract Symptoms; Male; Prostatic Diseases; Thiazoles | 2022 |
A phase III randomized trial of the timing of meloxicam with iodine-125 prostate brachytherapy.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Brachytherapy; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; Edema; Humans; Iodine Radioisotopes; Male; Meloxicam; Middle Aged; Ontario; Prostatic Diseases; Thiazines; Thiazoles; Urinary Retention | 2010 |
1 other study(ies) available for thiazoles and Prostatic Diseases
| Article | Year |
|---|---|
Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk.
Topics: Acetanilides; Adult; Aged; Aged, 80 and over; Catheterization; Cohort Studies; Female; Humans; Incidence; Male; Middle Aged; Muscarinic Antagonists; Prostatic Diseases; Randomized Controlled Trials as Topic; Residual Volume; Risk; Solifenacin Succinate; Thiazoles; Treatment Outcome; Urinary Bladder, Overactive; Urinary Retention; Urodynamics; Urological Agents | 2017 |